Skye Bioscience Inc (SKYE)

$3.62 +0.75 (26.13%)
Market Cap 88.90M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,291,800
Avg Vol 1,230,496
Day's Range N/A - N/A
Shares Out 30.98M
Stochastic %K 98%
Beta 1.69
Analysts Strong Sell
Price Target $16.67

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
StriveToSurvive
StriveToSurvive Jun. 25 at 9:39 AM
$SKYE
0 · Reply
StockScanners
StockScanners Jun. 25 at 4:35 AM
$SKYE Reached 4.26
0 · Reply
Multipliers
Multipliers Jun. 24 at 8:55 PM
$SKYE
0 · Reply
Raxothus
Raxothus Jun. 24 at 7:54 PM
EOD sniper setups for overnight holds: $CSAI — cleanest move today. Closed at HOD with strong volume and VWAP support. Breakout structure is there. Watching for $2.40+ push in premarket. $SKYE — solid trend day, holding above VWAP. Needs to reclaim $3.70+ with conviction to open the upside. $VYNE — thin float, strong trend late. Watching for a $1.10+ break tomorrow, but only if volume holds. All 3 qualify under the Power Hour continuation strategy. Small overnight starter only, no hope holds. Discipline, structure, and follow-through. Execution is everything.
0 · Reply
RiskRewardLab
RiskRewardLab Jun. 24 at 7:46 PM
$SKYE Another bio going wild! ATER the next big runner 90m$ revenues + share repurchase program + no dilution + new products released this month. 62% gross margin on revenues.
0 · Reply
builderup
builderup Jun. 24 at 7:45 PM
Nice 2 day run. Let’s keep it going! Scaling out but still strong. Patience $CAMP $SKYE $INTS
0 · Reply
aricray
aricray Jun. 24 at 7:43 PM
$SKYE Assuredly
1 · Reply
StriveToSurvive
StriveToSurvive Jun. 24 at 7:39 PM
$SKYE only more to come here. You can sell but I’m sure you’ll look back wondering where this stock has gone since you’ve left
1 · Reply
StriveToSurvive
StriveToSurvive Jun. 24 at 7:33 PM
$SKYE
0 · Reply
StriveToSurvive
StriveToSurvive Jun. 24 at 7:31 PM
$SKYE we rise!
0 · Reply
Latest News on SKYE
Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 2 days ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 8 days ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025, 7:00 AM EDT - 4 weeks ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 5 weeks ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 6 weeks ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 6 weeks ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 6 weeks ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 6 weeks ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025, 7:00 AM EDT - 7 weeks ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 29, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16, 2025, 7:50 AM EDT - 2 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

Apr 15, 2025, 3:42 PM EDT - 2 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 15, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Apr 14, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 9:58 PM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Mar 14, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 20, 2025, 7:00 AM EST - 4 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Skye Bioscience Announces Participation in February Conferences

Feb 4, 2025, 7:00 AM EST - 5 months ago

Skye Bioscience Announces Participation in February Conferences

MoneyShow's Best Investment Ideas For 2025: Part 8

Feb 3, 2025, 9:20 AM EST - 5 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 6 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10, 2024, 8:32 AM EST - 7 months ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 14, 2024, 7:00 AM EST - 7 months ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:36 PM EST - 8 months ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 7, 2024, 4:01 PM EST - 8 months ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience to Announce Third Quarter 2024 Results

Nov 1, 2024, 7:00 AM EDT - 8 months ago

Skye Bioscience to Announce Third Quarter 2024 Results

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

Oct 21, 2024, 7:00 AM EDT - 8 months ago

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

Oct 9, 2024, 1:13 PM EDT - 9 months ago

3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn't Ignore

RENT SCWO

Skye: Moving Weight Loss Drugs To The Next Level

Sep 4, 2024, 11:26 AM EDT - 10 months ago

Skye: Moving Weight Loss Drugs To The Next Level

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Aug 26, 2024, 7:00 AM EDT - 10 months ago

Skye Bioscience to Participate in Upcoming Healthcare Investment Conferences

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Aug 22, 2024, 7:00 AM EDT - 10 months ago

Skye Bioscience Launches Phase 2 CBeyond Clinical Trial of its Differentiated CB1 Inhibitor, Nimacimab, in Patients with Obesity

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Aug 21, 2024, 10:00 AM EDT - 10 months ago

Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Aug 19, 2024, 11:00 AM EDT - 11 months ago

Investors With Losses In Skye Bioscience Inc Are Urged To Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Aug 18, 2024, 11:00 AM EDT - 11 months ago

Skye Bioscience Inc Shareholders Encouraged Be A Part Of Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Aug 17, 2024, 11:00 AM EDT - 11 months ago

Skye Bioscience Inc Investors Invited To Partake In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 16, 2024, 11:00 AM EDT - 11 months ago

Skye Bioscience Inc Shareholders Encouraged To Join In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Aug 15, 2024, 11:00 AM EDT - 11 months ago

Skye Bioscience Inc Investors Encouraged To Join In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 10:30 PM EDT - 11 months ago

Skye Bioscience Inc Investors Urged To Participate In Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Aug 14, 2024, 12:40 AM EDT - 11 months ago

Skye Bioscience Inc Investors Encouraged To Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Aug 13, 2024, 2:00 AM EDT - 11 months ago

Skye Bioscience Inc Investors Urged To Join The Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Aug 9, 2024, 8:30 PM EDT - 11 months ago

Skye Bioscience Inc Investors Encouraged to Participate in Fraud Investigation With The Schall Law Firm

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 9, 2024, 5:59 PM EDT - 11 months ago

Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience Inc Investors Can Join Fraud Investigation With The Schall Law Firm

Aug 8, 2024, 9:30 PM EDT - 11 months ago

Skye Bioscience Inc Investors Can Join Fraud Investigation With The Schall Law Firm

Skye Bioscience Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm

Aug 7, 2024, 3:30 PM EDT - 11 months ago

Skye Bioscience Inc Investors Are Eligible To Join Fraud Investigation With The Schall Law Firm

StriveToSurvive
StriveToSurvive Jun. 25 at 9:39 AM
$SKYE
0 · Reply
StockScanners
StockScanners Jun. 25 at 4:35 AM
$SKYE Reached 4.26
0 · Reply
Multipliers
Multipliers Jun. 24 at 8:55 PM
$SKYE
0 · Reply
Raxothus
Raxothus Jun. 24 at 7:54 PM
EOD sniper setups for overnight holds: $CSAI — cleanest move today. Closed at HOD with strong volume and VWAP support. Breakout structure is there. Watching for $2.40+ push in premarket. $SKYE — solid trend day, holding above VWAP. Needs to reclaim $3.70+ with conviction to open the upside. $VYNE — thin float, strong trend late. Watching for a $1.10+ break tomorrow, but only if volume holds. All 3 qualify under the Power Hour continuation strategy. Small overnight starter only, no hope holds. Discipline, structure, and follow-through. Execution is everything.
0 · Reply
RiskRewardLab
RiskRewardLab Jun. 24 at 7:46 PM
$SKYE Another bio going wild! ATER the next big runner 90m$ revenues + share repurchase program + no dilution + new products released this month. 62% gross margin on revenues.
0 · Reply
builderup
builderup Jun. 24 at 7:45 PM
Nice 2 day run. Let’s keep it going! Scaling out but still strong. Patience $CAMP $SKYE $INTS
0 · Reply
aricray
aricray Jun. 24 at 7:43 PM
$SKYE Assuredly
1 · Reply
StriveToSurvive
StriveToSurvive Jun. 24 at 7:39 PM
$SKYE only more to come here. You can sell but I’m sure you’ll look back wondering where this stock has gone since you’ve left
1 · Reply
StriveToSurvive
StriveToSurvive Jun. 24 at 7:33 PM
$SKYE
0 · Reply
StriveToSurvive
StriveToSurvive Jun. 24 at 7:31 PM
$SKYE we rise!
0 · Reply
Multipliers
Multipliers Jun. 24 at 7:27 PM
$SKYE Every bull should post a thought, insight or projection today! Let's have some fun here while Polsky, et al., are napping. This is our week, let's celebrate with some conversation.
1 · Reply
Multipliers
Multipliers Jun. 24 at 7:20 PM
$SKYE That must have been one hell of a conference they had this week! Lots of new traders and investors! $5 clearly in sight!
0 · Reply
pgyletsgo
pgyletsgo Jun. 24 at 6:45 PM
$SKYE can’t be traded on Wells Fargo why?
0 · Reply
aricray
aricray Jun. 24 at 5:15 PM
$SKYE If I may repeat myself: Don't forget that the last round of PIPE was a $40 million raise at $10/share.
0 · Reply
J_THunder77
J_THunder77 Jun. 24 at 4:35 PM
$SKYE should be easliy 5$ with all the outperfrom ratings from analysts. Not selling until $20 maybe even holding that depending on our chances of a major buyout 🚀💰
1 · Reply
InstinctInvestor
InstinctInvestor Jun. 24 at 3:16 PM
$SKYE LOOKS LIKE S SWING
0 · Reply
YazzJr
YazzJr Jun. 24 at 3:01 PM
$SKYE Once we get above $4.13 there is not much resistance between that and the 52 week high of $8.44. So lets see.
1 · Reply
_www_larval_com_
_www_larval_com_ Jun. 24 at 2:38 PM
$SKYE has soared 3% higher to 13% (~4Mv) a few minutes ago, 07/18 options, follow for more volatility.
0 · Reply
trader013
trader013 Jun. 24 at 2:19 PM
$SKYE holding my diamond bag, very
0 · Reply
RunningRobert1
RunningRobert1 Jun. 24 at 2:03 PM
$SKYE Skye Bioscience SKYE Data Coming This Year! 23Jun2025 https://youtu.be/rWj8ZKFCFMw I posted this yesterday but in case you didnt see it before, we are looking for data this year, and since my first video for SKYE the stock is up 100%. I think we are gearing up for a great run up!
1 · Reply
JarvisFlow
JarvisFlow Jun. 24 at 1:49 PM
JMP Securities has adjusted their stance on Skye Bioscience ( $SKYE ), setting the rating to Market Outperform with a target price of 15.
0 · Reply
Finanz
Finanz Jun. 24 at 1:30 PM
$SKYE Up 11% in the pre-market
0 · Reply